Glycoprofiling of early non-small cell lung cancer using lectin microarray technology
Author:
Zeng Lingyan1, Xian Jinghong2, Chen Hongyu3, Mao Shengqiang1, Liu Lei1, Zhang Li1
Affiliation:
1. Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Networks , West China Hospital, Sichuan University , Chengdu , Sichuan , China 2. Department of Clinical Research Management , West China Hospital, Sichuan University , Chengdu , Sichuan , China 3. Key Laboratory of Transplantation Engineering and Immunology, Ministry of Health , West China Hospital, Sichuan University , Chengdu , Sichuan , China
Abstract
Abstract
Objectives
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world with a high incidence and it lacks effective biomarkers for early-stage detection. In this investigation, we aimed to investigate the alterations in plasma glycans related to NSCLC and assess the possibility of plasma glycopatterns as potential biomarkers for the diagnosis of NSCLC.
Methods
First, plasma samples from 16 patients with early-stage lung adenocarcinoma (LUAD), 16 patients with early-stage Lung squamous cell carcinoma (LUSC), and 16 healthy volunteers, were selected for inclusion in this study to probe the difference in plasma glycopatterns using lectin microarrays. Then, the diagnostic effectiveness of the candidate lectins was evaluated using ROC.
Results
In contrast to the NL group, seven candidate lectins offered potential diagnostic utility in the NSCLC (LUAD and LUSC) group. F17AG was significantly altered in LUSC with an AUC of 0.818 (adj.P.Val<0.05) compared to NL samples. There were 20 differentially expressed lectins in the LUAD group compared to the NL group. Based on the AUC values (AUC>0.800) and the normalized fluorescence intensities of the lectins, we selected eight lectins, GAL2, PTL-1, GNA, SSA, LENTIL, CA, PHA-E, and MAA to perform logistic regression analysis, and found that the combination of these eight candidate lectins had high diagnostic potential.
Conclusions
The results of this study should help to distinguish between NSCLC and NL based on changes in plasma glycopatterns, which have a great deal of potential to be biomarkers for diagnosing NSCLC.
Funder
The National Natural Science Foundation of China The Fundamental Research Funds for the Central Universities The Science and Technology Achievement Transformation Fund of West China Hospital of Sichuan University The Hospital Enterprise Cooperative Clinical Research Innovation Project
Publisher
Walter de Gruyter GmbH
Reference37 articles.
1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. https://doi.org/10.3322/caac.21332. 2. Auperin, A, Le Pechoux, C, Rolland, E, Curran, WJ, Furuse, K, Fournel, P, et al.. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90. https://doi.org/10.1200/jco.2009.26.2543. 3. Martin-Sanchez, JC, Lunet, N, Gonzalez-Marron, A, Lidon-Moyano, C, Matilla-Santander, N, Cleries, R, et al.. Projections in breast and lung cancer mortality among women: a bayesian analysis of 52 countries worldwide. Cancer Res 2018;78:4436–42. https://doi.org/10.1158/0008-5472.can-18-0187. 4. Zheng, M. Classification and pathology of lung cancer. Surg Oncol Clin N Am 2016;25:447–68. https://doi.org/10.1016/j.soc.2016.02.003. 5. Travis, WD, Brambilla, E, Nicholson, AG, Yatabe, Y, Austin, JHM, Beasley, MB, et al.. The 2015 world Health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243–60. https://doi.org/10.1097/jto.0000000000000630.
|
|